FOLFIRI (standard of care) clinical trials

Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

This study looks at a new drug combination (FOLFIRI + Zimberelimab + Domvanalimab) for a rare, aggressive cancer called neuroendocrine carcinoma. It compares this new treatment to the standard FOLFIRI chemotherapy for people whose cancer has returned after initial treatment.